|
Original version Date:24/08/2016
|
| bet | 349/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Original version Date:24/08/2016
|
Author: NMF Consensus Group/TC
|
Current Version number: 2
|
Current Version Date: 19/04/2018
|
Risk Rating: Low
|
Due for Review: 19/04/23
|
Approval by: DTC
|
Approval Date:
|
Meropenem |
Revision Date : 11-12-2020
|
Approve : TC, KOH
|
Alert
|
The Antimicrobial Stewardship Team recommends this drug is listed under the following category: Restricted.
Widespread use of carbapenems has been linked with increasing prevalence of infections caused by methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), multi-resistant Gram-negative organisms and Clostridium difficile.
|
Indication
|
Severe infections (e.g., sepsis or meningitis) caused by Gram-negative organisms resistant to other conventional antibiotics but susceptible to meropenem e.g., Extended Spectrum Beta Lactamase (ESBL)-producing organisms.
Note: Meropenem is NOT active against many resistant Gram-positive organisms, such as MRSA and most Staphylococcus epidermidis. Vancomycin is first-line therapy for these. Meropenem does have activity against penicillin-susceptible Gram-positive organisms and most anaerobic organisms. For individual advice, discuss therapy with a microbiologist or infectious diseases physician.
|
Action
|
Meropenem is a carbapenem. It inhibits cell wall synthesis. (1)
Meropenem is a better choice than imipenem for central nervous system infections. Meropenem attains a higher concentration in the cerebrospinal fluid particularly with inflamed meninges and has a lower incidence of seizures than imipenem.
|
Drug type
|
Carbapenem antibiotic.
|
Trade name
|
Meropenem APOTEX, Meropenem DBL, Meropenem GH, Meropenem Juno, Meropenem Kabi, Meropenem Sandoz, Merrem
|
Presentation
|
500 mg vial
1000 mg vial
|
Dose
|
|
|
| |
